MCID: BRS049
MIFTS: 55

Breast Carcinoma in Situ malady

Cancer diseases category

Summaries for Breast Carcinoma in Situ

About this section
Sources:
32MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
MalaCards: Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to breast cancer and ductal carcinoma in situ. An important gene associated with Breast Carcinoma in Situ is LIF (leukemia inhibitory factor), and among its related pathways are CREB Pathway and Malaria. The compounds cycloheximide and tamoxifen have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes, and related mouse phenotypes are limbs/digits/tail and adipose tissue.

Aliases & Classifications for Breast Carcinoma in Situ

About this section
Sources:
8Disease Ontology, 56SNOMED-CT, 60UMLS, 39NCIt, 27ICD9CM, 25ICD10
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases


Aliases & Descriptions:

breast carcinoma in situ 8
non-infiltrating carcinoma of breast 8
carcinoma in situ of breast 8


External Ids:

Disease Ontology8 DOID:8791
NCIt39 C3641
ICD9CM27 233.0
ICD1025 D05

Related Diseases for Breast Carcinoma in Situ

About this section
Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Breast Benign Neoplasm
breast carcinoma in situ Familial Breast Cancer
Chek2-Related Susceptibility to Breast Cancer Bard1-Related Susceptibility to Breast Cancer
Brip1-Related Breast Cancer Breast Cancer, Type 3
Breast Cancer, Early-Onset

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 152)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer30.7BRCA1, BRCA2
2ductal carcinoma in situ30.7BRCA1, BRCA2, CDH1, ERBB2, TP53
3ovarian cancer30.2BRCA1, BRCA2, MET, LIF, VEGFC, CDH1
4in situ carcinoma11.0
5breast apocrine carcinoma10.2
6poland syndrome10.2
7breast apocrine carcinoma in situ10.2
8female breast carcinoma10.1
9breast disease10.1
10pituitary adenoma10.0LIF
11malaria10.0LIF
12angiosarcoma10.0VEGFC
13dermatitis10.0LIF
14cervical intraepithelial neoplasia10.0VEGFC
15ischemia10.0VEGFC
16von hippel-lindau disease10.0MET
17chordoma10.0KRT19
18dilated cardiomyopathy10.0IL6ST
19nephritis10.0LIF
20breast-ovarian cancer, familial, 210.0BRCA2
21acute leukemia10.0IL6ST
22multiple endocrine neoplasia10.0BRCA2
23colon adenocarcinoma10.0CDH1
24gallbladder cancer10.0TP53
25neuroblastoma10.0TP53
26gastritis10.0TP53
27infertility10.0IL6ST, LIF
28prolactinoma10.0IL6ST, LIF
29proliferative diabetic retinopathy10.0MET
30ulcerative colitis10.0TP53
31teratoma10.0LIF
32pheochromocytoma10.0LIF, IL6ST
33uterine carcinosarcoma10.0ERBB2
34hepatoblastoma10.0LIF, MET
35leiomyosarcoma10.0TP53
36pemphigus vulgaris10.0CDH1
37werner syndrome10.0BRCA1
38gastrointestinal system disease10.0CDH1
39papilloma10.0TP53
40wilms tumor10.0VEGFC, BRCA2
41chondrosarcoma10.0KRT19, MET
42cystadenoma10.0BRCA1, VEGFC
43hereditary diffuse gastric cancer10.0CDH1
44malignant mesothelioma10.0CDH1, MET
45bilateral breast cancer10.0BRCA1, BRCA2
46neutropenia10.0ERBB2, LIF
47aplastic anemia10.0BRCA2, BRCA1
48laryngeal benign neoplasm10.0TP53, VEGFC
49liver cirrhosis10.0TGFB1
50biliary tract neoplasm10.0MET, ERBB2

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to breast carcinoma in situ

Clinical Features for Breast Carcinoma in Situ

About this section

Drugs & Therapeutics for Breast Carcinoma in Situ

About this section
Sources:
5CenterWatch, 41NIH Clinical Center, 6ClinicalTrials
See all sources

Approved drugs:

Search CenterWatch for Breast Carcinoma in Situ

Drug clinical trials:

Search ClinicalTrials for Breast Carcinoma in Situ

Search NIH Clinical Center for Breast Carcinoma in Situ

Search CenterWatch for Breast Carcinoma in Situ

Genetic Tests for Breast Carcinoma in Situ

About this section

Anatomical Context for Breast Carcinoma in Situ

About this section
Sources:
32MalaCards
See all sources

MalaCards organs/tissues related to Breast Carcinoma in Situ:

32
Breast, Lymph node, Testes, Smooth muscle, Cervix

Animal Models for Breast Carcinoma in Situ or affiliated genes

About this section
Sources:
36MGI
See all sources

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

36 (show all 23)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537110.2BRCA2
2MP:000537510.1LIF
3MP:00053919.9LIF
4MP:00053809.6KRT19, ERBB2
5MP:00053699.5MET, TP53, TGFB1
6MP:00053769.4BRCA1, BRCA2, LIF, IL6ST
7MP:00036318.4LIF, IL6ST, KRT19, ERBB2, TGFB1
8MP:00053888.2BRCA1, MET, LIF, IL6, ERBB2, TP53
9MP:00053708.2MET, LIF, IL6, IL6ST, TP53, TGFB1
10MP:00053908.1BRCA1, BRCA2, LIF, IL6, IL6ST, KRT19
11MP:00053977.9BRCA2, LIF, IL6, IL6ST, TP53, TGFB1
12MP:00020067.8TGFB1, MET, CDH1, IL6, KRT19, ERBB2
13MP:00053897.6BRCA1, BRCA2, LIF, CDH1, KRT19, ERBB2
14MP:00053797.4BRCA1, BRCA2, LIF, IL6, IL6ST, KRT19
15MP:00028737.4BRCA1, BRCA2, MET, CDH1, IL6ST, KRT19
16MP:00053867.4BRCA1, BRCA2, OSM, MET, LIF, IL6
17MP:00053876.8BRCA1, BRCA2, MET, LIF, VEGFC, CDH1
18MP:00053856.5VEGFC, LIF, MET, BRCA1, CDH1, IL6
19MP:00053816.5LIF, MET, BRCA2, BRCA1, CDH1, IL6
20MP:00107716.5BRCA1, BRCA2, OSM, LIF, CDH1, IL6
21MP:00053786.4BRCA1, BRCA2, MET, LIF, CDH1, IL6
22MP:00053845.9CDH1, LIF, MET, BRCA2, BRCA1, IL6
23MP:00107685.7VEGFC, LIF, MET, BRCA2, BRCA1, CDH1

Publications for Breast Carcinoma in Situ

About this section
Sources:
50PubMed
See all sources

Articles related to Breast Carcinoma in Situ:

(show top 50)    (show all 608)
idTitleAuthorsYear
1
Progression from ductal carcinoma in situ to invasive breast cancer: revisited. (23890733)
2013
2
Detection of occult invasion in ductal carcinoma in situ of the breast with sentinel node metastasis. (23281914)
2013
3
Prospective multicenter trial evaluating balloon-catheter partial-breast irradiation for ductal carcinoma in situ. (24074922)
2013
4
Overexpression of Aldo-keto reductase family 1 B10 protein in ductal carcinoma in situ of the breast correlates with HER2 positivity. (23912490)
2013
5
Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. (23774990)
2013
6
Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship. (23539741)
2013
7
Should ductal carcinoma-in-situ (DCIS) be removed from the ASTRO consensus panel cautionary group for off-protocol use of accelerated partial breast irradiation (APBI)? A pooled analysis of outcomes for 300 patients with DCIS treated with APBI. (23054123)
2013
8
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. (22253459)
2012
9
Twenty-year outcomes after breast-conserving surgery and definitive radiotherapy for mammographically detected ductal carcinoma in situ. (22644510)
2012
10
A rare case of extensive ductal carcinoma in situ of the breast with secretory features. (23372916)
2012
11
Our orientation regarding the ductal carcinoma in situ of the breast. (23110914)
2012
12
Rapid increase in incidence of breast ductal carcinoma in situ in Girona, Spain 1983-2007. (22340960)
2012
13
Sentinel lymph node involvement in ductal carcinoma in-situ of the breast: two different causes. (23040005)
2012
14
The role of preoperative bilateral breast magnetic resonance imaging in patient selection for partial breast irradiation in ductal carcinoma in situ. (22655183)
2012
15
Long-term outcome in patients with ductal carcinoma in situ treated with breast-conserving therapy: implications for optimal follow-up strategies. (22417804)
2012
16
Ductal carcinoma in situ of the breast. (22852075)
2012
17
Pyoderma gangrenosum of the breast after bilateral simple mastectomies for ductal carcinoma in situ. (21944335)
2011
18
Predictors of local recurrence in a population-based cohort of women with ductal carcinoma in situ treated with breast conserving surgery alone. (20645008)
2011
19
14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. (19732720)
2009
20
Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. (18683965)
2008
21
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. (17200343)
2007
22
In situ production of sex steroids in human breast carcinoma. (17874044)
2007
23
Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence. (17649807)
2007
24
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. (17397528)
2007
25
Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. (16430472)
2006
26
Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? (15832086)
2005
27
Correlation of HER2 gene amplification with expression of the apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast. (15722788)
2005
28
Proliferative lesions of the breast: carcinoma in situ. (15022899)
2003
29
Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. (14612904)
2003
30
Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast? (12704442)
2003
31
Heterogeneous versus homogeneous genetic nature of multiple foci of in situ carcinoma of the breast. (14652818)
2003
32
Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. (14648660)
2003
33
The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. (12481013)
2002
34
Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. (11381366)
2001
35
Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. (11564211)
2001
36
Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. (11176072)
2001
37
The p53 tumor suppressor gene in ductal carcinoma in situ of the breast. (10623646)
2000
38
Recent trends of in situ carcinoma of the breast and mammographic screening in the Florence area, Italy. (10482490)
1999
39
Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. (9815604)
1997
40
Vascularity of proliferative breast disease and carcinoma in situ correlates with histological features. (9816143)
1996
41
Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma. (8840971)
1996
42
Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. (8758245)
1996
43
Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. (8097877)
1993
44
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. (1548522)
1992
45
Expression of p53 protein in infiltrating and in-situ breast carcinomas. (1684809)
1991
46
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. (1657650)
1991
47
Estrogen receptors in ductal carcinoma in situ of breast. (2164337)
1990
48
In situ carcinoma of the breast. (2543266)
1989
49
Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. (2990246)
1985
50
Small-cell dysplasia and in situ carcinoma of the breast: incidence and age distribution in patients biopsied over a 29-year period. (1084466)
1976

Genetic Variations for Breast Carcinoma in Situ

About this section

Expression for genes affiliated with Breast Carcinoma in Situ

About this section
Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for genes affiliated with Breast Carcinoma in Situ

About this section
Sources:
51QIAGEN, 29KEGG, 12EMD Millipore, 59Tocris Bioscience, 53Reactome, 37NCBI BioSystems Database, 52R&D Systems, 55SinoBiological
See all sources

Pathways related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show top 50)    (show all 55)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Hide members
10.2VEGFC
210.0SDC1
310.0SDC1
4
Hide members
10.0VEGFC, MET
5
Hide members
9.8MET, IL6
69.7TP53, BRCA1
79.7TGFB1, IL6
8
Hide members
9.7TP53, ERBB2
9
Hide members
9.6VEGFC, ERBB2, MET
10
Hide members
9.6SDC1, TGFB1
11
Hide members
9.6TGFB1, SDC1
129.6LIF, VEGFC, IL6
13
Hide members
9.6VEGFC, CDH1, ERBB2
149.5MET, CDH1, ERBB2
159.4TP53, BRCA2, BRCA1
16
Hide members
9.4BRCA2, BRCA1, TP53
17
DNA damage Role of Brca1 and Brca2 in DNA repair
Hide members
9.4BRCA2, BRCA1, TP53
189.4ERBB2, MET, TP53
199.4TP53, ERBB2, CDH1
209.3TGFB1, IL6ST, LIF
219.3MET, TGFB1, SDC1
229.2TGFB1, TP53, IL6
239.2IL6, IL6ST, ERBB2
24
Hide members
9.2TGFB1, VEGFC, MET, IL6
25
Cytokine production by Th17 cells in CF (Mouse model)
9.2IL6, IL6ST, TGFB1
26
Hide members
9.2IL6, TGFB1, IL6ST
279.2TGFB1, IL6, IL6ST
289.2CDH1, TP53, VEGFC, BRCA1
299.1MET, BRCA1, TP53, ERBB2
309.1BRCA1, TP53, CDH1, BRCA2
319.1LIF, OSM, IL6ST
32
Hide members
9.1CDH1, ERBB2, TP53, MET
33
Hide members
9.0TGFB1, BRCA2, ERBB2, TP53
34
Translation Insulin regulation of translation
Hide members
9.0ERBB2, TGFB1, IL6ST, MET
35
Hide members
9.0IL6ST, ERBB2, LIF, IL6
36
Immune response Oncostatin M signaling via JAK-Stat in human cells
Hide members
8.9IL6ST, IL6, OSM
37
G-protein signaling Ras family GTPases in kinase cascades (scheme)
Hide members
8.9TP53, IL6ST, OSM
38
Transcription Androgen Receptor nuclear signaling
Hide members
8.8IL6ST, ERBB2, TGFB1, IL6
398.7TP53, ERBB2, BRCA2, BRCA1, TGFB1
408.7TP53, IL6ST, IL6, TGFB1
418.5ERBB2, SDC1, MET, TP53, TGFB1
42
Hide members
8.4MET, LIF, VEGFC, ERBB2, TGFB1, OSM
438.3LIF, TGFB1, IL6ST, IL6, OSM
448.3TP53, ERBB2, IL6, CDH1, BRCA2, TGFB1
458.2MET, BRCA1, OSM, TP53, IL6, VEGFC
46
Hide members
8.1TP53, TGFB1, ERBB2, IL6, VEGFC, BRCA2
47
Hide members
7.6TGFB1, LIF, VEGFC, IL6, IL6ST, ERBB2
48
Hide members
7.5ERBB2, OSM, MET, LIF, VEGFC, IL6
49
Hide members
7.4OSM, IL6ST, ERBB2, LIF, IL6, VEGFC
50
Hide members
6.9TGFB1, BRCA1, OSM, MET, TP53, ERBB2

Compounds for genes affiliated with Breast Carcinoma in Situ

About this section
Sources:
44Novoseek, 49PharmGKB, 28IUPHAR, 11DrugBank, 24HMDB, 59Tocris Bioscience, 2BitterDB
See all sources

Compounds related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show top 50)    (show all 120)
idCompoundScoreTop Affiliating Genes
1cycloheximide4410.3BRCA1, BRCA2
2tamoxifen44 49 28 1112.8TGFB1, ERBB2, CDH1
3pge2449.7CDH1, TGFB1, MET, VEGFC
4estradiol44 11 2411.6VEGFC, OSM, BRCA2
5il 11449.5IL6, LIF, OSM
6indole-3-carbinol449.5BRCA2, CDH1, BRCA1, TP53
7methylcellulose449.4IL6, LIF, TGFB1, CDH1
8heparin44 28 11 2412.3ERBB2, CDH1, LIF, BRCA1
94-hydroxytamoxifen449.3TGFB1, BRCA2, ERBB2, BRCA1
10vitamin d449.3IL6ST, IL6, ERBB2, MET
11depsipeptide449.1TP53, OSM, CDH1, LIF
12bleomycin44 1110.1BRCA1, BRCA2, TP53, TGFB1
13bortezomib44 1110.0BRCA1, TP53, ERBB2, IL6
145fluorouracil449.0TP53, ERBB2, CDH1, BRCA1, LIF
15matrigel449.0LIF, BRCA2, CDH1, KRT19, MET
16ifn-alpha448.9IL6, LIF, OSM, IL6ST
17pdtc448.9MET, TGFB1, TP53, IL6
18carboplatin44 49 1110.9TP53, ERBB2, LIF, BRCA1
19tgf beta1448.8OSM, TGFB1, IL6, CDH1, LIF
20herbimycin a44 599.8CDH1, ERBB2, MET, IL6, OSM
21methotrexate44 49 1110.8CDH1, BRCA2, BRCA1, TGFB1, IL6, ERBB2
22curcumin448.8CDH1, TGFB1, TP53, ERBB2, IL6
23docetaxel44 49 59 1111.8BRCA2, TGFB1, BRCA1, TP53, ERBB2, CDH1
24etoposide44 49 59 1111.8TGFB1, CDH1, BRCA2, BRCA1, TP53, ERBB2
25doxorubicin44 49 1110.8BRCA1, MET, CDH1, ERBB2, TGFB1, TP53
26p002448.5BRCA1, MET, CDH1, KRT19, BRCA2, ERBB2
27proline448.5TP53, CDH1, BRCA2, BRCA1, IL6ST, MET
28phosphotyrosine448.5OSM, MET, CDH1, IL6ST, ERBB2, BRCA1
29ly294002448.5CDH1, TP53, IL6, ERBB2, TGFB1, VEGFC
30pd 98,059448.4TGFB1, IL6, MET, OSM, CDH1, VEGFC
31ribonucleic acid448.4TGFB1, IL6ST, KRT19, VEGFC, MET, LIF
32agar448.3OSM, BRCA1, MET, LIF, CDH1, IL6ST
33hyaluronic acid44 249.2CDH1, OSM, IL6, KRT19, TGFB1
34oligonucleotide448.2BRCA1, MET, IL6ST, TGFB1, TP53, VEGFC
35steroid448.2OSM, LIF, BRCA1, BRCA2, KRT19, ERBB2
36lactate448.1IL6, LIF, CDH1, TGFB1, ERBB2, KRT19
37dexamethasone44 49 28 1111.1IL6ST, IL6, LIF, OSM, CDH1, TGFB1
38paclitaxel44 49 119.8TP53, LIF, BRCA1, BRCA2, ERBB2, TGFB1
39phosphatidylinositol447.7VEGFC, IL6ST, BRCA1, OSM, MET, ERBB2
40alanine447.7TGFB1, ERBB2, BRCA1, IL6ST, IL6, CDH1
41testosterone44 59 11 2410.7BRCA2, IL6, LIF, VEGFC, CDH1, ERBB2
42genistein44 28 59 2 11 2412.6ERBB2, IL6ST, IL6, CDH1, LIF, MET
43cisplatin44 49 59 1110.5BRCA1, BRCA2, MET, CDH1, KRT19, ERBB2
44serine447.3BRCA1, TGFB1, OSM, LIF, CDH1, IL6ST
45paraffin447.3KRT19, ERBB2, VEGFC, TGFB1, CDH1, TP53
46progesterone44 59 28 11 2411.1BRCA1, BRCA2, MET, LIF, ERBB2, IL6ST
47thymidine44 247.9BRCA1, TGFB1, TP53, KRT19, BRCA2, VEGFC
48tyrosine446.8OSM, MET, VEGFC, LIF, CDH1, IL6
49retinoic acid44 247.0KRT19, TGFB1, TP53, IL6ST, IL6, CDH1
50vegf446.0TGFB1, TP53, KRT19, IL6ST, IL6, CDH1

GO Terms for genes affiliated with Breast Carcinoma in Situ

About this section
Sources:
16Gene Ontology
See all sources

Cellular components related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1interleukin-6 receptor complexGO:0058969.7IL6ST, IL6
2oncostatin-M receptor complexGO:0059009.4IL6ST, OSM
3focal adhesionGO:0059259.1SDC1, CDH1, BRCA1
4protein complexGO:0432348.8BRCA1, BRCA2, TP53, SDC1
5extracellular regionGO:0055768.1VEGFC, IL6, IL6ST, SDC1, TGFB1, MET
6extracellular spaceGO:0056158.1OSM, LIF, VEGFC, IL6, IL6ST, TGFB1

Biological processes related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show all 32)
idNameGO IDScoreTop Affiliating Genes
1cellular response to indole-3-methanolGO:07168110.2CDH1, BRCA1
2leukemia inhibitory factor signaling pathwayGO:04886110.0LIF, IL6ST
3tyrosine phosphorylation of Stat3 proteinGO:0425039.9LIF, OSM
4positive regulation of astrocyte differentiationGO:0487119.9LIF, IL6ST
5positive regulation of tyrosine phosphorylation of Stat1 proteinGO:0425119.9LIF, IL6ST
6positive regulation of histone deacetylationGO:0310659.9TP53, TGFB1
7negative regulation of neuroblast proliferationGO:0074069.9TP53, TGFB1
8negative regulation of meiosisGO:0458359.9OSM, LIF
9negative regulation of cell-cell adhesionGO:0224089.8TGFB1, CDH1
10positive regulation of histone acetylationGO:0350669.8TGFB1, BRCA1
11interleukin-6-mediated signaling pathwayGO:0701029.8IL6, IL6ST
12DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:0069789.8TP53, BRCA2, BRCA1
13positive regulation of blood vessel endothelial cell migrationGO:0435369.7VEGFC, TGFB1
14double-strand break repairGO:0063029.7BRCA1, BRCA2, TP53
15positive regulation of cell cycle arrestGO:0711589.7BRCA1, TP53, TGFB1
16positive regulation of tyrosine phosphorylation of Stat3 proteinGO:0425179.7IL6ST, IL6, LIF
17negative regulation of hormone secretionGO:0468889.6IL6, LIF, OSM
18positive regulation vascular endothelial growth factor productionGO:0105759.6TGFB1, IL6ST
19positive regulation of cell divisionGO:0517819.6TGFB1, VEGFC, OSM
20positive regulation of MAPK cascadeGO:0434109.5IL6, LIF, OSM
21positive regulation of epithelial cell proliferationGO:0506799.5VEGFC, IL6, ERBB2, TGFB1
22response to X-rayGO:0101659.4TP53, BRCA2
23response to drugGO:0424939.4VEGFC, CDH1, IL6, TGFB1
24positive regulation of acute inflammatory responseGO:0026759.3OSM, IL6, IL6ST
25positive regulation of peptidyl-serine phosphorylationGO:0331389.2TGFB1, IL6, LIF, OSM
26positive regulation of peptidyl-tyrosine phosphorylationGO:0507319.1OSM, LIF, IL6, TP53
27cell proliferationGO:0082838.9OSM, MET, ERBB2, TP53
28negative regulation of cell proliferationGO:0082858.7OSM, LIF, IL6, TP53, TGFB1
29positive regulation of transcription, DNA-dependentGO:0458938.7BRCA1, BRCA2, CDH1, IL6, TP53, TGFB1
30modulation by virus of host morphology or physiologyGO:0190488.4TGFB1, TP53, KRT19, IL6ST
31positive regulation of cell proliferationGO:0082848.4OSM, LIF, VEGFC, IL6, IL6ST, TGFB1
32positive regulation of transcription from RNA polymerase II promoterGO:0459448.2BRCA1, OSM, MET, LIF, IL6, TP53

Molecular functions related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1interleukin-6 receptor bindingGO:0051389.5IL6ST, IL6
2protein phosphatase bindingGO:0199039.2MET, CDH1, ERBB2
3growth factor activityGO:0080838.6TGFB1, IL6, VEGFC, LIF, OSM
4protein bindingGO:0055155.9VEGFC, MET, BRCA2, BRCA1, CDH1, IL6ST

Products for genes affiliated with Breast Carcinoma in Situ

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Breast Carcinoma in Situ

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
50PubMed
51QIAGEN
57SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet